Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-daily rivaroxaban for prevention of VTE after elective total hip replacement (ODIXaHIP-OD)
2004-001341-14Phase 2Completed
- Sponsor
- Bayer
- Start
- Sep 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rivaroxaban in venous thromboembolism (VTE), deep vein thrombosis (DVT) and pulmonary embolism (PE) (2 arms), sponsored by Bayer. Primary endpoint: Primary composite efficacy endpoint. Started Sep 2004; status: completed.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on 2004-001341-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001341-14.